BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit

July 17, 2020

BioSig Technologies, Inc. Adopts Stockholder Rights Agreement

July 16, 2020

Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites

July 13, 2020

BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government

July 10, 2020

ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

July 8, 2020

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

July 1, 2020

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

June 29, 2020

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

June 24, 2020

ViralClear Partners with Catalent on Potential Treatment for COVID-19

June 22, 2020

ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19

June 17, 2020